Hyperfibrinolysis increases blood-brain barrier permeability by a plasmin-and bradykinin-dependent mechanism

Blood

Volumn 128, Issue 20, 2016, Pages 2423-2434

  Marcos Contreras, Oscar A ^a   De Lizarrondo, Sara Martinez ^a   Bardou, Isabelle ^a   Orset, Cyrille ^a   Pruvost, Mathilde ^a   Anfray, Antoine ^a   Frigout, Yvann ^a   Hommet, Yannick ^a   Lebouvier, Laurent ^a   Montaner, Joan ^b   Vivien, Denis ^a,c   Gauberti, Maxime ^a,d  

^a UNIVERSITÉ DE CAEN   (France)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c Department of Cell Biology ^*  (France)

^d CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINO 3 CYCLOPROPYLAMINO 7 (4 ISOPROPYLBENZYL) 7H PYRROLO[3,2 F]QUINAZOLINE; AMINOCAPROIC ACID; APROTININ; BIOLOGICAL MARKER; BRADYKININ; BRADYKININ B2 RECEPTOR; CP 471474; DIZOCILPINE; HIGH MOLECULAR WEIGHT KININOGEN; IBA 1 PROTEIN; ICATIBANT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN RECEPTOR; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PEPTIDES AND PROTEINS; PLASMIN; PLASMINOGEN; PROTEINASE ACTIVATED RECEPTOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UROKINASE; VASCULAR CELL ADHESION MOLECULE 1; BRADYKININ B2 RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; BLEEDING DISORDER; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CONTROLLED STUDY; EXTRAVASATION; FIBRINOLYTIC THERAPY; FLUORESCENCE IMAGING; FLUORESCENCE IMAGING SYSTEM; GENE DELETION; GENE OVEREXPRESSION; HOMEOSTASIS; HUMAN; HYDRODYNAMICS BASED TRANSFECTION; HYPERFIBRINOLYSIS; MOLECULAR PATHOLOGY; MOUSE; NEAR INFRARED IMAGING SYSTEM; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PLASMID; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; ANIMAL; BRAIN; CAPILLARY PERMEABILITY; DRUG EFFECTS; FIBRINOLYSIS; GENETICS; HYDRODYNAMICS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; BLOOD-BRAIN BARRIER; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONISTS; BRAIN; CAPILLARY PERMEABILITY; FIBRINOLYSIN; FIBRINOLYSIS; HYDRODYNAMICS; MICE; MICE, TRANSGENIC; RECEPTOR, BRADYKININ B2; SIGNAL TRANSDUCTION; TISSUE PLASMINOGEN ACTIVATOR;

EID: 85006667118     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-03-705384     Document Type: Article

References (44)

1. Raza I, Davenport R, Rourke C, et al. The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost. 2013; 11(2):307-314.
2. Rijken DC, Kock EL, Guimaraes AH, et al. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. J Thromb Haemost. 2012; 10(10):2116-2122.
3. Schö chl H, Cadamuro J, Seidl S, et al. Hyperfibrinolysis is common in out-of-hospital cardiac arrest: results from a prospective observational thromboelastometry study. Resuscitation. 2013;84(4):454-459.
4. Breen KA, Grimwade D, Hunt BJ. The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia. Br J Haematol. 2012;156(1):24-36.
5. Shakur H, Roberts I, Bautista R, et al; CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010; 376(9734):23-32.
6. Roullet S, Freyburger G, Labrouche S, et al. Hyperfibrinolysis during liver transplantation is associated with bleeding. Thromb Haemost. 2015; 113(5):1145-1148.
7. Marx I, Christophe OD, Lenting PJ, et al. Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa. Blood. 2008;112(3):603-609.
8. von Drygalski A, Furlan-Freguia C, Mosnier LO, Yegneswaran S, Ruf W, Griffin JH. Infrared fluorescence for vascular barrier breach in vivo-a novel method for quantitation of albumin efflux. Thromb Haemost. 2012;108(5): 981-991.
9. Jaffer H, Adjei IM, Labhasetwar V. Optical imaging to map blood-brain barrier leakage. Sci Rep. 2013;3:3117.
10. Lopez-Atalaya JP, Roussel BD, Levrat D, et al. Toward safer thrombolytic agents in stroke: molecular requirements for NMDA receptor-mediated neurotoxicity. J Cereb Blood Flow Metab. 2008;28(6):1212-1221.
11. Nicole O, Docagne F, Ali C, et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med. 2001;7(1):59-64.
12. Parcq J, Bertrand T, Baron AF, Hommet Y, Anglès-Cano E, Vivien D. Molecular requirements for safer generation of thrombolytics by bioengineering the tissue-type plasminogen activator A chain. J Thromb Haemost. 2013;11(3): 539-546.
13. Niego B, Medcalf RL. Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis? J Cereb Blood Flow Metab. 2014;34(8): 1283-1296.
14. Vivien D, Gauberti M, Montagne A, Defer G, Touzé E. Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence. J Cereb Blood Flow Metab. 2011;31(11):2119-2134.
15. Gauberti M, Montagne A, Quenault A, Vivien D. Molecular magnetic resonance imaging of brain-immune interactions. Front Cell Neurosci. 2014; 8:389.
16. Montagne A, Gauberti M, Macrez R, et al. Ultrasensitive molecular MRI of cerebrovascular cell activation enables early detection of chronic central nervous system disorders. Neuroimage. 2012;63(2):760-770.
17. Gauberti M, Montagne A, Marcos-Contreras OA, Le Bé hot A, Maubert E, Vivien D. Ultra-sensitive molecular MRI of vascular cell adhesion molecule-1 reveals a dynamic inflammatory penumbra after strokes. Stroke. 2013;44(7):1988-1996.
18. Belliere J, Martinez de Lizarrondo S, Choudhury RP, et al. Unmasking Silent Endothelial Activation in the Cardiovascular System Using Molecular Magnetic Resonance Imaging. Theranostics. 2015;5(11):1187-1202.
19. Mannaioni G, Orr AG, Hamill CE, et al. Plasmin potentiates synaptic N-methyl-D-aspartate receptor function in hippocampal neurons through activation of protease-activated receptor-1. J Biol Chem. 2008;283(29):20600-20611.
20. Suzuki Y, Nagai N, Umemura K, Collen D, Lijnen HR. Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice. J Thromb Haemost. 2007;5(8): 1732-1739.
21. Wang X, Lee SR, Arai K, et al. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med. 2003;9(10):1313-1317.
22. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest. 2003;112(10):1533-1540.
23. Carmo AA, Costa BR, Vago JP, et al. Plasmin induces in vivo monocyte recruitment through protease-activated receptor-1-, MEK/ERK-, and CCR2-mediated signaling. J Immunol. 2014; 193(7):3654-3663.
24. Borlongan CV, Emerich DF. Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport. Brain Res Bull. 2003;60(3):297-306.
25. Briens A, Gauberti M, Parcq J, Montaner J, Vivien D, Martinez de Lizarrondo S. Nano-zymography Using Laser-Scanning Confocal Microscopy Unmasks Proteolytic Activity of Cell-Derived Microparticles. Theranostics. 2016;6(5):610-626.
26. Gando S. Hemostasis and thrombosis in trauma patients. Semin Thromb Hemost. 2015;41(1): 26-34.
27. Truong HT, Browning RM. Anaphylaxis-induced hyperfibrinolysis in pregnancy. Int J Obstet Anesth. 2015;24(2):180-184.
28. Jácomo RH, Santana-Lemos BA, Lima AS, et al. Methionine-induced hyperhomocysteinemia reverts fibrinolytic pathway activation in a murine model of acute promyelocytic leukemia. Blood. 2012;120(1):207-213.
29. Xie R, Gao C, Li W, et al. Phagocytosis by macrophages and endothelial cells inhibits procoagulant and fibrinolytic activity of acute promyelocytic leukemia cells. Blood. 2012; 119(10):2325-2334.
30. Polavarapu R, Gongora MC, Yi H, et al. Tissue-type plasminogen activator-mediated shedding of astrocytic low-density lipoprotein receptor-related protein increases the permeability of the neurovascular unit. Blood. 2007;109(8): 3270-3278.
31. Su EJ, Fredriksson L, Geyer M, et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med. 2008;14(7):731-737.
32. Niego B, Freeman R, Puschmann TB, Turnley AM, Medcalf RL. t-PA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes. Blood. 2012;119(20): 4752-4761.
33. Hill MD, Lye T, Moss H, et al. Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke. Neurology. 2003;60(9): 1525-1527.
34. Molinaro G, Gervais N, Adam A. Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach. Stroke. 2002;33(6): 1712-1716.
35. Zamolodchikov D, Chen ZL, Conti BA, Renné T, Strickland S. Activation of the factor XII-driven contact system in Alzheimer's disease patient and mouse model plasma. Proc Natl Acad Sci USA. 2015;112(13):4068-4073.
36. Montagne A, Barnes SR, Sweeney MD, et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron. 2015;85(2):296-302.
37. Sharma HS. A bradykinin BK2 receptor antagonist HOE-140 attenuates blood-spinal cord barrier permeability following a focal trauma to the rat spinal cord. An experimental study using Evans blue, [131]I-sodium and lanthanum tracers. Acta Neurochir Suppl (Wien). 2000;76:159-163.
38. Kwaan HC, Wang J, Weiss I. Expression of receptors for plasminogen activators on endothelial cell surface depends on their origin. J Thromb Haemost. 2004;2(2):306-312.
39. Karaszewski B, Houlden H, Smith EE, et al. What causes intracerebral bleeding after thrombolysis for acute ischaemic stroke? Recent insights into mechanisms and potential biomarkers. J Neurol Neurosurg Psychiatry. 2015;86(10):1127-1136.
40. Gauberti M, Martinez de Lizarrondo S, Orset C, Vivien D. Lack of secondary microthrombosis after thrombin-induced stroke in mice and non-human primates. J Thromb Haemost. 2014;12(3): 409-414.
41. Su J, Cui M, Tang Y, Zhou H, Liu L, Dong Q. Blockade of bradykinin B2 receptor more effectively reduces postischemic blood-brain barrier disruption and cytokines release than B1 receptor inhibition. Biochem Biophys Res Commun. 2009;388(2):205-211.
42. Langhauser F, Göb E, Kraft P, et al. Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage, and inflammation. Blood. 2012;120(19):4082-4092.
43. Martins AH, Alves JM, Perez D, et al. Kinin-B2 receptor mediated neuroprotection after NMDA excitotoxicity is reversed in the presence of kinin-B1 receptor agonists. PLoS One. 2012;7(2): e30755.
44. Kunz M, Nussberger J, Holtmannspötter M, Bitterling H, Plesnila N, Zausinger S. Bradykinin in blood and cerebrospinal fluid after acute cerebral lesions: correlations with cerebral edema and intracranial pressure. J Neurotrauma. 2013; 30(19):1638-1644.